Approved accessible "ado-trastuzumab emtansine for injection"

Ado-Trastuzumab emtansine also known as ado-trastuzumab emtansine and sold under the trade name Kadcyla, is an antibody-drug conjugate consisting of the humanized monoclonal antibody trastuzumab (Herceptin) covalently linked to the cytotoxic agent DM1. Trastuzumab alone stops growth of cancer cells by binding to the HER2 receptor, whereas trastuzumab emtansine undergoes receptor-mediated internalization into cells, is catabolized in lysosomes where DM1-containing catabolites are released and subsequently bind tubulin to cause mitotic arrest and cell death.

How can 1 go about obtaining ado-trastuzumab emtansine for injection?

To access ado-trastuzumab emtansine for injection sold under the brand name can be made available on request to patient if the drug has not been approved or is not available in your country. For information or advice, call IPN's Pharmaceutical Expert. Our expert will be happy to take your query and guide with an effective solution. Be free and call today for full support at +91 9891 296 838 (Mr. Tarun) / +91 9811 747 774 (Mr. Neeraj)

KADCYLA (ado-trastuzumab emtansine) for injection, for intravenous use Initial U.S. Approval: {YYYY}

References

• Full prescribing information [FDA]: Kadcyla (trastuzumab emtansine) [PDF], Genentech, May 2019.
• Kadcyla Breastcancer.org
• Australian Product Information [TGA]: Kadcyla (trastuzumab emtansine) [PDF], Roche, Sep 2019.
• U.S. Food and Drug Administration. FDA approves ado-trastuzumab emtansine for early breast cancer. 06/05/2019 (last update: 06/05/2019), cited on 10/03/2020.
• Summary of Product Characteristics [EMA]: Kadcyla (trastuzumab emtansine) [PDF], Roche, Jan 2020.